Rani Therapeutics Holdings Inc (NASDAQ: RANI) kicked off on Tuesday, up 4.14% from the previous trading day, before settling in for the closing price of $0.42. Over the past 52 weeks, RANI has traded in a range of $0.39-$3.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 4.78% over the last five years. While this was happening, its average annual earnings per share was recorded 12.86%. With a float of $23.90 million, this company’s outstanding shares have now reached $33.57 million.
The firm has a total of 105 workers. Let’s measure their productivity. In terms of profitability, gross margin is 49.32%, operating margin of -4989.69%, and the pretax margin is -4773.25%.
Rani Therapeutics Holdings Inc (RANI) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Rani Therapeutics Holdings Inc is 45.17%, while institutional ownership is 5.84%. The most recent insider transaction that took place on Dec 13 ’24, was worth 29,993. In this transaction Chief Business Officer of this company bought 17,960 shares at a rate of $1.67, taking the stock ownership to the 17,960 shares. Before that another transaction happened on Dec 09 ’24, when Company’s Chief Executive Officer bought 10,296 for $1.94, making the entire transaction worth $19,974. This insider now owns 494,751 shares in total.
Rani Therapeutics Holdings Inc (RANI) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 12.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.63% during the next five years compared to 4.78% growth over the previous five years of trading.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) Trading Performance Indicators
Take a look at Rani Therapeutics Holdings Inc’s (RANI) current performance indicators. Last quarter, stock had a quick ratio of 0.88. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.78 in one year’s time.
Technical Analysis of Rani Therapeutics Holdings Inc (RANI)
Analysing the last 5-days average volume posted by the [Rani Therapeutics Holdings Inc, RANI], we can find that recorded value of 1.84 million was better than the volume posted last year of 1.23 million. As of the previous 9 days, the stock’s Stochastic %D was 7.80%.
During the past 100 days, Rani Therapeutics Holdings Inc’s (RANI) raw stochastic average was set at 4.18%, which indicates a significant decrease from 10.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0651 in the past 14 days, which was lower than the 0.0800 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5599, while its 200-day Moving Average is $1.3971. Now, the first resistance to watch is $0.4529. This is followed by the second major resistance level at $0.4685. The third major resistance level sits at $0.4869. If the price goes on to break the first support level at $0.4189, it is likely to go to the next support level at $0.4005. Now, if the price goes above the second support level, the third support stands at $0.3849.
Rani Therapeutics Holdings Inc (NASDAQ: RANI) Key Stats
The company with the Market Capitalisation of 29.56 million has total of 63,208K Shares Outstanding. Its annual sales at the moment are 1,030 K in contrast with the sum of -30,020 K annual income. Company’s last quarter sales were recorded 170 K and last quarter income was -7,260 K.